Results 61 to 70 of about 436,254 (306)

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Erratum: ‘I am afraid the news is not good’ – Breaking bad news in the time of COVID: Experiences from a field hospital

African Journal of Primary Health Care & Family Medicine
No abstract available.
Charmaine Cunningham, Pat Mayers, Janet Giddy, Magdaleen de Swardt, Peter Hodkinson   +4 more
doaj   +1 more source

Características epidemiológicas, clínicas y evolutivas de los pacientes pediátricos con enfermedades crónicas y limitantes, susceptibles de recibir atención por cuidados paliativos en el Hospital Pablo Tobón Uribe, Medellín, Colombia

Medicina U.P.B., 2018
Objetivo: en pediatría, los pacientes susceptibles de recibir cuidados paliativos pueden tener una supervivencia larga pero una vida limitada o amenazada por la enfermedad que padecen, por lo tanto, no solo es importante conocer las causas de muerte sino
Mussatye Elorza Parra, Alberto García-Salido, César Vanegas Díaz, Mauricio Fernández Laverde   +3 more
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Temporal Trends in Mortality Location Among Patients With Intrahepatic Cholangiocarcinoma in the USA: A Retrospective Observational Analysis of National Center for Health Statistics Mortality Data

JGH Open
Objectives Intrahepatic cholangiocarcinoma (ICC) is a malignancy with rising incidence and mortality in the United States. This study aimed to investigate temporal trends in the place of death among patients with ICC and assess demographic disparities ...
Muhammad Ahmad Nadeem, Abdullah Khan, Ahsan Raza Raja, Usama Hussain Kamal, Abdul Rafeh Awan, Jibran Ikram, Asad Ullah, Marjan Khan, Abu Baker Sheikh, Amir Humza Sohail   +9 more
doaj   +1 more source

Benefits and Harms of Antibiotic Use in End-of-Life Patients: Retrospective Study in Palliative Care

Antibiotics
Context: Many patients at the end of life receive antibiotics to alleviate symptoms and improve quality of life; however, clear guidelines supporting decision making about the use of antibiotics are still lacking. Objectives: This study aimed to evaluate
Rita Faustino Silva, Joana Brandão Silva, António Pereira Neves, Daniel Canelas, João Rocha Neves, José Paulo Andrade, Marília Dourado, Hugo Ribeiro   +7 more
doaj   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

The provision of informal care in terminal illness: An analysis of carers? needs using a discrete choice experiment [PDF]

There is an increasing expectation that families will provide care at home for those with chronic, acute and terminal illness. There is a range of services available to support the home care of these patients.
Patricia Kenny, Ishrat Hossain, Jane Hall   +2 more
core  

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source